Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 42 | 35 | 33 | 35 | 43 |
| Income taxes - deferred | 426 | N/A | N/A | N/A | N/A |
| Accounts receivable | 0 | 17 | -338 | 163 | -465 |
| Accounts payable and accrued liabilities | 50 | 72 | 17 | 42 | -474 |
| Other Working Capital | 1,572 | -1,203 | -793 | -531 | -969 |
| Other Operating Activity | -1,595 | -500 | -2,823 | -5,776 | -4,764 |
| Operating Cash Flow | $495 | $-1,579 | $-3,904 | $-6,067 | $-6,629 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | -15 | -46 | -26 | -41 |
| Other Investing Activity | 1 | 69 | -38 | -5 | -7 |
| Investing Cash Flow | $-15 | $54 | $-84 | $-31 | $-48 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 640 | N/A | N/A | N/A | N/A |
| Debt Repayment | -11 | -22 | -22 | -11 | -38 |
| Common Stock Issued | 93 | 891 | 1,555 | 0 | 3,914 |
| Other Financing Activity | 424 | 1,835 | 1,384 | 136 | 11,427 |
| Financing Cash Flow | $1,146 | $2,704 | $2,917 | $125 | $15,303 |
| Exchange Rate Effect | 53 | -56 | 9 | -128 | 84 |
| Beginning Cash Position | 5,008 | 3,885 | 4,947 | 11,048 | 2,338 |
| End Cash Position | 6,687 | 5,008 | 3,885 | 4,947 | 11,048 |
| Net Cash Flow | $1,626 | $1,179 | $-1,071 | $-5,973 | $8,626 |
| Free Cash Flow | |||||
| Operating Cash Flow | 495 | -1,579 | -3,904 | -6,067 | -6,629 |
| Capital Expenditure | -16 | -15 | -46 | -26 | -41 |
| Free Cash Flow | 479 | -1,594 | -3,950 | -6,093 | -6,670 |